Anki Malmborg Hager
Dr. Malmborg assumed the position as CEO in 2014. Before joining SenzaGen, Dr. Malmborg has worked for several small biotech companies, both as CEO and board member. She is the author of about 30 scientific papers and book chapters, and the inventor on a number of patents.
Marianne assumed the role as CFO in November 2016. Before joining SenzaGen Marianne has been working as Administrative and Financial Manager at the Department of Immunotechnology, Lund University.
Maria Agemark took on the position as Laboratory & Quality Manager at SenzaGen AB in the spring of 2015. She holds a PhD in Biochemistry at the Department of Chemistry, Lund University, with focus on membrane proteins, and postdoc studies in the field of antibody technology at the Department of Immunotechnology, Lund University.
Dr Smith is a European patent attorney at the firm of Potter Clarkson LLP, with expertise in biotech inventions including biomarker-based technologies. Together with his colleagues, Tom Harding and Lucy Mills, Steve advises SenzaGen in relation to all aspects of intellectual property rights and manages its growing IP portfolio. He became a consultant member of SenzaGen’s management team in early 2017.
Anna Chérouvrier Hansson
Anna Chérouvrier Hansson joined SenzaGen in August 2017. Anna holds a Master in European Business Administration and Business Law and a Bachelor degree in Business Administration. She brings extensive experience from senior roles in the life science industry with focus on commercialization strategies, business development, marketing and sales. Prior to joining SenzaGen, Anna was Director of Marketing & Medical Device Business Unit at Camurus and has previously held positions of increasing commercial responsibility in pharmaceutical, chemical and consulting companies.